Special Issue "20th Anniversary of Molecules—Recent Advances in Medicinal Chemistry"
Deadline for manuscript submissions: closed (15 December 2015)
Advisory Board Member
Prof. Dr. Osvaldo Andrade Santos-Filho
Twenty years! Can you believe it? In 2015 we are celebrating the 20th anniversary of our journal Molecules. The growth of Molecules has only been possible because authors, reviewers, editors, and all people working in some way for the journal have joined their efforts for years. Thank you for your confidence and your enthusiasm.
Molecules (ISSN 1420-3049) was initiated by Dr. Shu-Kun Lin in Switzerland in 1996 with the additional original idea of encouraging the repository and exchange of chemical samples. The early days were not easy, but in Volume 2, you could already read 232 pages covering an editorial, 26 interesting research papers, and 42 short notes belonging to the MolBank section (http://www.mdpi.com/journal/molecules/sections/molbank). What a successful road since that time! Indeed, volume 18 (2013) was completed with 15,803 pages and we can reasonably foresee that volume 19 (2014) will surpass 20,000 pages.
To mark that important milestone, a special issue entitled “Recent Advances in Medicinal Chemistry” is being launched. On behalf of the members of the Advisory Board created for the occasion, I kindly invite all groups involved in the field to contribute by submitting an up-to-date review, with the aim of providing to our readers a comprehensive survey of the many topics covered by the discipline.
Dr. Jean Jacques Vanden Eynde
Dr. Michael Berger
Dr. Osvaldo Andrade Santos-Filho
Dr. Sylvain Rault
Dr. Melanie T. Cushion
Advisory Board Members
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed Open Access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript.
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Type of Paper: Review article
Title: Mechanisms of flavonoids anti-inflammatory capacity: progress in the last decade
Authors: Andreia P. Oliveira, Paula B. Andrade and Patrícia Valentão
Affiliations: REQUIMTE/LAQV, Laboratório de Farmacognosia, Departamento de Química, Faculdade de Farmácia, Universidade do Porto, R. Jorge Viterbo Ferreira, n.º 228, 4050-313 Porto, Portugal
Abstract: Inflammation is a complex protective reaction caused by endogenous and exogenous factors. Increasing evidence suggests that activated macrophages play an important role in inflammation by the production of pro-inflammatory cytokines, tumor necrosis factor α (TNF-α), and other inflammatory mediators like nitric oxide (•NO) and prostaglandin E2 (PGE2). The overproduction of inflammatory mediators is involved in many diseases and the regulation of their production in tissues might be important for the treatment of inflammation. Flavonoids, polyphenolic plant secondary metabolites ubiquitously present in fruits and vegetables, possess interesting anti-inflammatory actions. The results of several epidemiological studies suggest that an increase in flavonoids intake is beneficial for inflammation. In fact, these metabolites inhibit transcription factors, such as nuclear factor-kappa B (NF-κB), nuclear factor-erythroid 2-related factor 2 (Nrf2), and activating protein-1 (AP-1).They are also known to inhibit the production of pro-inflammatory cytokines like interleukin 1β (IL-1β), IL-6 and TNF-α, as well as for their capacity to reduce •NO levels by scavenging or by inhibition of inducible nitric oxide synthase (iNOS) activity and/or expression. Furthermore, some flavonoids are able to inhibit key enzymes of the inflammatory cascade, such as phospholipase A2 (PLA2), lipoxygenase (LOX) and cyclooxygenase (COX). This review considers the advances in the knowledge of the anti-inflammatory potential of dietary flavonoids found in the last decade, by focusing their action mechanism and structure-activity relationships.
Type of Paper: Review
Title: Inhibitors of the Hydrolytic Enzyme Dimethylarginine Dimethylaminohydrolase (Ddah): Discovery, Synthesis, and Development
Authors: Rhys B. Murphy †, Sara Tommasi †, Benjamin C. Lewis and Arduino A. Mangoni *
Affiliation: Department of Clinical Pharmacology, Flinders University School of Medicine, Adelaide, Australia
† These authors Contributed equally to this manuscript
Author to whom correspondence should be addressed; E-Mail: email@example.com; Tel.: +61 8 8204 7495; Fax: +61 8 8204 5114
Abstract: Dimethylarginine dimethylaminohydrolase (DDAH) is a highly conserved hydrolytic enzyme found in numerous species including, bacteria, rodents, and humans. In humans, the DDAH-1 isoform is known to metabolize endogenous asymmetric dimethylarginine (ADMA) and monomethyl arginine (L-NMMA), with ADMA proposed to be a putative marker of cardiovascular disease. Current literature reports identify the DDAH family of enzymes as a potential therapeutic target in the regulation of vascular homeostasis, mediated via its biochemical interaction with the nitric oxide synthase (NOS) family of enzymes. Increased DDAH expression and nitric oxide production have been linked to multiple pathological conditions, specifically, cancer, neurodegenerative disorders, and septic shock. As such, the discovery, chemical synthesis, and development of DDAH small molecule inhibitors as potential drug candidates represent a growing field of interest. This review article summarizes the current knowledge on DDAH inhibition and compares the derived pharmacokinetic parameters of the main DDAH inhibitors reported in the literature. Furthermore, current methods of development and chemical synthetic pathways will be discussed.